Interferon alpha-2b - Lee's Pharmaceutical

Drug Profile

Interferon alpha-2b - Lee's Pharmaceutical

Alternative Names: Yallaferon

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata; Herpes zoster; Uterine cervicitis
  • Phase II/III Human papillomavirus infections

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 01 Sep 2015 Lee's Pharmaceutical initiates enrolment in a phase II/III trial for Human papillomavirus infections in China (NCT02801383)
  • 01 Sep 2015 Lee's Pharmaceutical initiates enrolment in a phase II trial for Human papillomavirus infections in China (NCT02593968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top